UNASSIGNED: Intensive @entity900 and oral @entity2879 for relapsed @entity43 ( @entity43 ), commonly known as the van der Burg (VDB) protocol, has been reported to improve response rates and progression-free survival. We report on all @entity1 with relapsed @entity43 treated on the VDB protocol at the Cambridge Gynae-Oncology Centre. From the institutional databases, we identified all @entity1 treated since 2001. We extracted demographic, clinical, treatment, and @entity137 data and outcomes. We used Cox regression to identify predictors of survival. A total of 35 @entity1 were treated on the VDB protocol. @entity137 was significant, with grade 3/4 fatigue, @entity390 and @entity391 affecting 46, 46 and 29% of @entity1 , respectively. Six @entity1 had grade 3/4 infection and four (11%) @entity204 occurred on treatment. Efficacy was encouraging, with a radiological response rate of 43%, a median progression-free survival of 5.8 months and a median overall survival of 14.1 months. No significant difference in efficacy was seen between @entity902 -resistant and sensitive @entity1 . We report significant activity of the VDB protocol in a routine clinical setting. However, the high rates of serious @entity137 and treatment-related @entity204 among @entity1 treated with palliative intent proved unacceptable. The Cambridge Gynae-Oncology Centre no longer uses this regimen in @entity1 with relapsed @entity43 .

Intensive XXXX /oral @entity2879 for @entity43 : the Cambridge Gynae-Oncology Centre experience: Too toxic for relapse?

@entity43 :: ('MESH:D010051', 'Disease') :: ['EOC', 'epithelial ovarian cancer'] @entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']
@entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']
